Health● Low35m ago · Nov 9, 2026, 6:52 PM
Tonix outlines TRAIL Phase II start in Q1 2027 enrolling ~3,300 for TNX-4800 as TONMYA patents run to 2034
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Tonix has outlined plans for the start of its TRAIL Phase II clinical trial in Q1 2027, intending to enroll approximately 3,300 participants for TNX-4800. This development is noted as patents for TONMYA extend until 2034.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Health
Not flagged as developing.
More in Health
Health28m agoCold therapy may be worse than doing nothing for post-exercise recoveryNew ScientistHealth1h agoRaptadu chainsaw attack victim’s condition improving, says A.P. Health MinisterThe HinduHealth1h agoFDA orders new warning on GLP-1s over rare eye condition linked to sudden blindnessNBC NewsHealth1h agoEthiopia: Reusable sanitary pads help girls break the silence around menstruationAfricanews [en]